Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Patients With BRAF Fusions or Non-V600 Mutations (MATCH Subprotocol R)
NCT04439279Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib in solid tumor, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Aug 2015; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
solid tumorlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439279.